Overview

• Mark Thierer, Waltz co-founder and EVERSANA chairman, will serve as chief executive of the combined organization.
• Company statements outline integration across patient services, field teams, digital marketing, reimbursement support and real‑world evidence using modern software.
• Waltz’s marketplaces and AI-enabled prescription routing promise direct-to-payer and direct-to-patient channels designed to broaden reach and improve affordability.
• The platform will add a URAC‑accredited specialty pharmacy network through Waltz Connect to support high‑cost and limited‑distribution therapies.
• Additional details such as deal close timing and regulatory milestones were not disclosed, while Thierer emphasizes a net‑price approach that avoids back‑end rebates.